1
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
-----------------
SCHEDULE 13G
(Rule 13d-102)
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT
TO RULES 13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED
PURSUANT TO RULE 13d-2(b)
(Amendment No. ____)(1)
Genetronics Biomedical, Ltd.
--------------------------------------------------------------------------------
(Name of Issuer)
Common Stock
--------------------------------------------------------------------------------
(Title of Class of Securities)
371916 10 7
--------------------------------------------------------------------------------
(CUSIP Number)
December 31, 1998
--------------------------------------------------------------------------------
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule
is filed:
[ ] Rule 13d-1(b)
[x] Rule 13d-1(c)
[ ] Rule 13d-1(d)
(1) The remainder of this cover page shall be filled out for a
reporting person's initial filing on this form with respect to the subject class
of securities, and for any subsequent amendment containing information which
would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not
be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange
Act of 1934, as amended (the "Act"), or otherwise subject to the liabilities of
that section of the Act but shall be subject to all other provisions of the Act
(however, see the Notes).
2
CUSIP No. 371916 10 7 13G Page 2 of 7 Pages
1. NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
Johnson & Johnson 22-1024240
--------------------------------------------------------------------------------
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) [ ]
(b) [ ]
--------------------------------------------------------------------------------
3. SEC USE ONLY
--------------------------------------------------------------------------------
4. CITIZENSHIP OR PLACE OF ORGANIZATION
New Jersey
--------------------------------------------------------------------------------
5. SOLE VOTING POWER 0
NUMBER OF --------------------------------------------------------------------
SHARES
BENEFICIALLY 6. SHARED VOTING POWER 2,242,611
OWNED BY
EACH --------------------------------------------------------------------
REPORTING
PERSON WITH 7. SOLE DISPOSITIVE POWER 0
--------------------------------------------------------------------------------
8. SHARED DISPOSITIVE POWER 2,242,611
--------------------------------------------------------------------------------
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,242,611
--------------------------------------------------------------------------------
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
[ ]
--------------------------------------------------------------------------------
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
8.2%
--------------------------------------------------------------------------------
12. TYPE OF REPORTING PERSON*
CO
--------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
3
CUSIP No. 371916 10 7 13G Page 3 of 7 Pages
--------------------------------------------------------------------------------
1. NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NO. OF ABOVE PERSONS (ENTITIES ONLY)
Johnson & Johnson Development Corporation 22-2007137
--------------------------------------------------------------------------------
2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) [ ]
(b) [ ]
--------------------------------------------------------------------------------
3. SEC USE ONLY
--------------------------------------------------------------------------------
4. CITIZENSHIP OR PLACE OF ORGANIZATION
New Jersey
--------------------------------------------------------------------------------
5. SOLE VOTING POWER 0
NUMBER OF ---------------------------------------------------------------------
SHARES
BENEFICIALLY 6. SHARED VOTING POWER 2,242,611
OWNED BY
EACH ---------------------------------------------------------------------
REPORTING
PERSON WITH 7. SOLE DISPOSITIVE POWER 0
--------------------------------------------------------------------------------
8. SHARED DISPOSITIVE POWER 2,242,611
--------------------------------------------------------------------------------
9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
2,242,611
--------------------------------------------------------------------------------
10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES*
[ ]
--------------------------------------------------------------------------------
11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9
8.2%
--------------------------------------------------------------------------------
12. TYPE OF REPORTING PERSON*
CO
--------------------------------------------------------------------------------
*SEE INSTRUCTIONS BEFORE FILLING OUT!
4
CUSIP No. 371916 10 7 13G Page 4 of 7 Pages
ITEM 1(a). NAME OF ISSUER:
Genetronics Biomedical, Ltd.
ITEM 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES:
11199 Sorrento Valley Road
San Diego, CA 92121-1334
ITEM 2(a). NAME OF PERSON FILING:
Johnson & Johnson ("J&J")
Johnson & Johnson Development Corporation ("JJDC")
ITEM 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE:
One Johnson & Johnson Plaza
New Brunswick, NJ 08933
ITEM 2(c). CITIZENSHIP:
J&J and JJDC are both New Jersey corporations
ITEM 2(d). TITLE OF CLASS OF SECURITIES:
Common Stock, no par value per share
Item 2(e). CUSIP Number:
371916 10 7
ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO RULE 13d-1(b), OR 13d-2(b) OR
(c), CHECK WHETHER THE PERSON FILING IS A:
(a) [ ] Broker or dealer registered under Section 15 of
the Exchange Act.
(b) [ ] Bank as defined in Section 3(a)(6) of the
Exchange Act.
(c) [ ] Insurance company as defined in Section 3(a)(19) of
the Exchange Act.
(d) [ ] Investment company as defined in Section 8 of the
Investment Company Act.
(e) [ ] An investment adviser in accordance with Rule
13d-1(b)(1)(ii)(E).
(f) [ ] An employee benefit plan or endowment fund in
accordance with Rule 13d-1(b)(1)(ii)(F).
5
CUSIP No. 371916 10 7 13G Page 5 of 7 Pages
(g) [ ] A parent holding company or control person in
accordance with Rule 13d-1(b)(1)(ii)(G).
(h) [ ] A savings association as defined in Section
3(b) of the Federal Deposit Insurance Act.
(i) [ ] A church plan that is excluded from the
definition of an investment company under Section
3(c)(14) of the Investment Company Act.
(j) [ ] Group, in accordance with Rule
13d-1(b)(1)(ii)(J).
N/A
ITEM 4. OWNERSHIP:
(a) Amount beneficially owned:
J&J 2,242,611
JJDC 2,242,611
(b) Percent of class:
J&J 8.2%
JJDC 8.2%
(c) Number of shares as to which such person has:
(i) Sole power to vote or to direct the vote: 0
(ii) Shared power to vote or to direct the vote:
J&J 2,242,611
JJDC 2,242,611
(iii) Sole power to dispose or to direct
the disposition of: 0
(iv) Shared power to dispose or to direct the disposition of:
J&J 2,242,611
JJDC 2,242,611
ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS:
If this statement is being filed to report the fact that as of the date hereof
the reporting person has ceased to be the beneficial owner of more than five
percent of a class of securities, check the following [ ].
N/A
6
CUSIP No. 371916 10 7 13G Page 6 of 7 Pages
ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF
OF ANOTHER PERSON:
N/A
ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH
ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING
COMPANY:
N/A
ITEM 8. IDENTIFICATION OF MEMBERS OF THE GROUP:
N/A
ITEM 9. NOTICE OF DISSOLUTION OF A GROUP:
N/A
ITEM 10. CERTIFICATION:
By signing below I certify that, to the best of my knowledge and
belief, the securities referred to above were not acquired and are not held for
the purpose of or with the effect of changing or influencing the control of the
issuer of the securities and were not acquired and are not held in connection
with or as a participant in any transaction having that purpose or effect.
7
CUSIP No. 371916 10 7 13G Page 7 of 7 Pages
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief,
I certify that the information set forth in this statement is true, complete and
correct.
JOHNSON & JOHNSON
Dated: March 21, 2001 By /s/ Michael H. Ullmann
---------------------------- -----------------------------
Name: Michael H. Ullmann
Title: Secretary
JOHNSON & JOHNSON DEVELOPMENT
CORPORATION
Dated: March 21, 2001 By /s/ Eric B. Jung
---------------------------- -----------------------------
Name: Eric B. Jung
Title: Secretary